Join Growin Stock Community!

Bright minds biosciences inc.DRUG.US Overview

US StockHealthcare
(No presentation for DRUG)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

DRUG AI Insights

DRUG Overall Performance

DRUG AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

DRUG Recent Performance

-3.70%

Bright minds biosciences inc.

0.05%

Avg of Sector

-0.31%

S&P500

DRUG PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

DRUG Key Information

DRUG Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

DRUG Profile

Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.

Price of DRUG

DRUG FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

DRUG Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.56
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
12.52
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.56
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
12.52
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is DRUG's latest earnings report released?

    The most recent financial report for Bright minds biosciences inc. (DRUG) covers the period of 2026Q1 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating DRUG's short-term business performance and financial health. For the latest updates on DRUG's earnings releases, visit this page regularly.

  • How much cash does DRUG have?

    At the end of the period, Bright minds biosciences inc. (DRUG) held Total Cash and Cash Equivalents of 89.05M, accounting for 0.98 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is DRUG's EPS continuing to grow?

    According to the past four quarterly reports, Bright minds biosciences inc. (DRUG)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.97. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of DRUG?

    Bright minds biosciences inc. (DRUG)'s Free Cash Flow (FCF) for the period is -5.82M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 289.18% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.